Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Other Events

ME Staff 8-k
-
0

Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Other Events
Item 8.01 Other Events.

On June 1, 2017, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company’s management will present an overview and update of the Company and host investor meetings at the Jefferies 2017 Global Healthcare Conference on June 7, 2017. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit  to Item 8.01 hereof:

Exhibit 99.1 — Press Release Dated June 1, 2017.


About Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Recent Trading Information

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) closed its last trading session up +1.30 at 40.05 with 1,468,026 shares trading hands.